INTRODUCTION AND OBJECTIVES:
Transrectal fusion biopsy (TRFBx) has become ubiquitous with multiple published series establishing its utility. Validation of transperineal fusion biopsy (TPFBx) is limited to a small single series. We aim to evaluate cancer detection rate (CDR; overall and high-grade) and 30-day complications of TRFBx vs TPFBx in the largest series to date.
METHODS: A review of the Michigan Urologic Surgery Improvement Collaborative (MUSIC) prospective registry of all patients undergoing TRFBx and TPFBx at a single practice was performed. TPFBx was performed under sedation using a electromagnetically tracked stepper and fusion platform for MR targets in addition to the Modified Barzell 12-core template. Patient, MRI, pathology characteristics, and 30-day complications were prospectively collected and analyzed. Multivariable analysis was performed to control for individual risk and PIRADS score. High grade CDR (hgCDR) was defined as GS ! 7.
RESULTS: A total of 398 TRFBx and 60 TPFBx were performed. (Table 1a) . There were no infection-related hospitalizations, sepsis episodes, UTI, fever, or episodes of retention after TPFbx at 30-days follow-up (Table 1b) . Infectious complications did occur after TRFbx, but were rare.
CONCLUSIONS: In our cohort, TPFBx was similar to TRFBx for cancer detection and pathologic upgrading. Early outcomes in a limited series of TPFbx demonstrated zero infectious complications within 30 days. Larger series with longer-term outcomes are needed.
Source of Funding: Blue Cross and Blue Shield
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